Thursday, 4 January 2018
For Lupin, uncertainties of 2018 would continue in 2019: Ramesh Swaminathan
Biosimilars, complex generics and speciality would be key elements of Lupin strategy going forward, says Ramesh Swaminathan , CFO and ED, Lupin, in an interview with ET Now. Swaminathan says 2018-19 would be bad years for the pharma company and they expect things to become better only in 2019-2020.
You can read more here: For Lupin, uncertainties of 2018 would continue in 2019: Ramesh Swaminathan
Subscribe to:
Post Comments (Atom)
Life insurers earn more in Oct selling lesser policies
The 24-company Indian life insurance industry closed last month with new business of Rs 22,776.03 crore, up by 31.87 per cent over the prev...
-
In an interview with ET Now, N Jayakumar, Prime Securities , says as people feel more comfortable about putting in SIP kind of flows into t...
-
The 24-company Indian life insurance industry closed last month with new business of Rs 22,776.03 crore, up by 31.87 per cent over the prev...
No comments:
Post a Comment